Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H21NO2 |
Molecular Weight | 259.3434 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@]1(CCC=C[C@@H]1NC)C2=CC=CC=C2
InChI
InChIKey=PDJZPNKVLDWEKI-GOEBONIOSA-N
InChI=1S/C16H21NO2/c1-3-19-15(18)16(13-9-5-4-6-10-13)12-8-7-11-14(16)17-2/h4-7,9-11,14,17H,3,8,12H2,1-2H3/t14-,16+/m0/s1
Molecular Formula | C16H21NO2 |
Molecular Weight | 259.3434 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:28:15 GMT 2023
by
admin
on
Sat Dec 16 10:28:15 GMT 2023
|
Record UNII |
7145G6817J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-Nortilidine
Created by
admin on Sat Dec 16 10:28:15 GMT 2023 , Edited by admin on Sat Dec 16 10:28:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
38677-94-0
Created by
admin on Sat Dec 16 10:28:15 GMT 2023 , Edited by admin on Sat Dec 16 10:28:15 GMT 2023
|
PRIMARY | |||
|
162321
Created by
admin on Sat Dec 16 10:28:15 GMT 2023 , Edited by admin on Sat Dec 16 10:28:15 GMT 2023
|
PRIMARY | |||
|
77829
Created by
admin on Sat Dec 16 10:28:15 GMT 2023 , Edited by admin on Sat Dec 16 10:28:15 GMT 2023
|
PRIMARY | |||
|
7145G6817J
Created by
admin on Sat Dec 16 10:28:15 GMT 2023 , Edited by admin on Sat Dec 16 10:28:15 GMT 2023
|
PRIMARY | |||
|
DTXSID10191973
Created by
admin on Sat Dec 16 10:28:15 GMT 2023 , Edited by admin on Sat Dec 16 10:28:15 GMT 2023
|
PRIMARY | |||
|
Nortilidine
Created by
admin on Sat Dec 16 10:28:15 GMT 2023 , Edited by admin on Sat Dec 16 10:28:15 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
Inhibition of forskolin-induced cAMP accumulation.
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE LESS ACTIVE -> PARENT |
Shows six times less affinity to Mu-receptor than nortilidine
|
||
|
PRODRUG -> METABOLITE ACTIVE |
After oral intake tilidine is completely absorbed and rapidly metabolised to nortilidine, bisnortilidine. 100 fold more active than Tilidine.
|